Key
Management
We are a pharmaceutical development company
with experienced executives and a shared vision
to improve the standard of cancer care.
Ningfeng Fiona Li, MD, PhD, MSc
Chief Executive Office &
Chief Medical Officer
Specialist in Clinical Oncology, with extensive research experience in tumour biology and carcinogenesis with publications in high impact journals.
Founder of London Nanjing Life Science (China) Ltd and Suzhou NG Biomedicine Ltd and developed several biotech reagent products, disinfectant products and small molecule pharmaceutical products through prototyping, clinical trials and recently marketing.
Gary Bower, BSc
Chief Operating Officer
Specialist in managing Clinical Trials, with over 25 years' experience managing studies across all phases, primarily in oncology.
Founder of GTE Consultancy Ltd, supporting small biotechnology companies with clinical & pre-clinical development since 2006.
Hilary Birrell, BSc
Head of Clinical Operations
Biochemist and Clinical Trial Specialist with over 30 years' experience in multiple indications across Phases I-IV of Drug Development. Early career in AstraZeneca followed by 20 years of consultancy experience. Owner/Director of Carnegie Clinical Research Ltd, Clinical Trial Management CRO, since 2010.
Joseph Irwin, BSc, MSc, MRSB, CBiol, FTOPRA, FRSM, FRSS FZS
Chief Regulatory Adviser
Biochemist/ Pharmacologist by training with experience in Clinical Trials, animal models, cell biology and molecular biology techniques. Joseph has 30 years as a regulatory professional in all therapeutic areas, in the EU, US and international markets; formal J&J Director of Regulatory Affairs EU, founder of LRCS Ltd.
Austin Smith,
Deputy Chief Medical Officer
Trained and qualified in Medical Oncology and Pharmaceutical Medicine, Austin has a solid background in all aspects of Oncology and Malignant Hematology, along with Regulatory Science experience across Europe, the US and Asia-Pacific regions, acting in senior and executive positions in biopharma companies. Austin is also a member of the Expert Group for Oncology, representing the Faculty of Pharmaceutical Medicine in the UK
Sheila Johnson,
People & Culture Consultant
Sheila brings to Vaso Dynamics over 30 years of People & Culture experience within Healthcare and Life Sciences. Overseeing and ensuring we are compliant with Employment Legislation, Sheila is also a Strategic and Operational Partner to the Executive Team. As the business continues to grow, Sheila will support the team in establishing and fostering a great culture, enhancing engagement and managing communications.
Emma Palmer-Foster,
Business Development Consultant
As EJ Palmer Consulting, Emma Palmer Foster works with pharma and biotech companies/organisations on strategy, investor relations and communications.
Emma has more than 30 years of experience in the European healthcare sector, via roles in investment banking, VC, financial communications and investor relations, journalism and technology transfer. She chairs a UK NIHR Invention for Innovation (i4i) Product Development Award Panel, is a Director of Discovery Park Ventures and Investor Director/Observer at portfolio companies.
Emma has an MA in Biochemistry from the University of Oxford and an MBA from Durham University Business School.
Dr Andrew Leinster, PhD
Head of Pre-clinical Research
Andrew is a dedicated preclinical scientist with over 20 years' experience in academia, biotech and pharmaceutical companies. With a historical focus on developing immune therapies (e.g. modified RNA and Oncolytic viruses) to increase the patient benefit whilst minimising of side effects. "It is the reduction of side effects and the improvement of cancer patients' quality of life that has led me to join VasoDynamics."